DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Diamond-Blackfan anemia — screening already-approved drugs against its 31-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDiamond-Blackfan anemia maps to a 31-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for diamond-blackfan anemia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
tumor protein p53 (TP53) — TP53 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9R2Q · 3.2 Å · ligand none (apo structure). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Revista chilena de pediatría · 2000 · 1 citations · open access
Anemia de Diamond-Blackfan: Experiencia clínica en 20 pacientes (1968-1998)
AbstractDiamond Blackfan syndrome is an uncommon cause of anaemia in newborns and infants. We analyzed the clinical features and laboratory results of 20 patients, followed over a period of 30 years. We found that in 85% of cases the diagnosis was made in the first year, and the majority were female. 45% of patients had low weights for date at birth. The most important characteristic in the physical examination, apart from pallor, was short stature, in most cases there were no other physical abnormalities. 100% registered haemoglobin levels below normal, macrocytosis and reticulocytopenia, without affecting other haematological series. 85% of cases had a positive response to corticosteroids. Of the 3 non-responders 2 died and 1 survived with a dependence on red cell transfusions and secondary iron overload, as a lack of donors made a bone marrow transplant impossible. In this group transplant should be considered as the most appropriate treatment as other alternatives have had little success.
Powikłania terapii niedokrwistości Blackfana i Diamonda – studium dwóch przypadków klinicznych
AbstractDiamond–Blackfan anemia (DBA) is a rare congenital hypoplastic anemia, diagnosed most frequently in early childhood. Since 1936, when it was first reported, many methods have been proposed for the treatment of the disease. Some of those are still used nowadays, though the rest have gone out of practice in the history of medicine. These approaches are broadly discussed in the literature in terms of their efficacy and safety. Low occurrence of the disease explains small number of systematic reports focusing of this clinical problem. In this article, we present two case reports of patients diagnosed with Diamond–Blackfan anemia, who were treated in the Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin with different therapeutic strategies depending on the course of the disease.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
